Table 1.

Baseline patient and disease characteristics

	N=30
Sex
Male	19 (63)
Female	11 (37)
Age, years
Median (IQR)	67 (58–69)
ECOG performance status
0	8 (27)
1	22 (73)
Biliary tract cancer classification
Gallbladder cancer	12 (40)
Intrahepatic cholangiocarcinoma	10 (33)
Extrahepatic cholangiocarcinoma	7 (23)
Ampullary cancer	1 (3)
Number of prior anticancer therapies*
1	26 (87)
2	3 (10)
3	1 (3)
PD-L1 expression†
Positive	16 (53)
Negative	13 (43)
Not evaluable	1 (3)
HBV/HCV positivity
HBsAg	1 (3)
HBsAb	8 (27)
HBcAb	13 (43)
HBV-DNA	0
HCV Ab	0
Immune phenotype status
Immune-desert	3 (10)
Immune-excluded	23 (77)
Inflamed	2 (7)
Not evaluable	2 (7)

Data are n (%) unless otherwise specified.

Positive: PD-L1 expression in ≥1% of tumor cells; negative: PD-L1 expression in <1% of tumor cells.

*Include neoadjuvant and adjuvant therapies.

†Defined as the proportion of tumor cells showing membranous PD-L1 staining.

HCV Ab, antibody [NOTE: THIS IS PUTTING HCV Ab IN PROOF. SHOULD BE: "Ab, antibody"]; ECOG, Eastern Cooperative Oncology Group; HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B virus surface antibody; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HBV-DNA, hepatitis B virus DNA; HCV, hepatitis C virus; PD-L1, programmed death ligand 1.